Phase 3 funding and FDA alignment confirmed, but quarterly loss missed expectations

The strategic outcome was already largely expected. The FDA’s alignment with a 12-month registrational Phase 3 design and the $275 million private placement were announced before this filing—FDA feedback on June 22, 2026, and the financing on July 27, 2026—so the 8-K mainly confirms rather than newly changes the investment case. The financing is expected to fund EB613 through topline Phase 3 results and an anticipated NDA submission, with operations supported into 2030 (Cash and cash equivalents).

The reported quarterly loss was worse than the published expectation. Net loss was $0.14 per share versus a published consensus of approximately $0.09 per share loss, a miss of about $0.05 per share.

The EPS miss is less alarming than the headline suggests. The filing attributes $2.7 million of the loss increase to a non-cash fair-value remeasurement of pre-funded warrants issued in April, while the higher research spending reflects preparation for EB613’s Phase 3 program and the OPKO collaboration (Net loss; Research and development expenses). That makes the miss financially unfavorable versus expectations, but not evidence of an equivalent deterioration in the underlying development program.

The net read is mixed: execution is funded, but little new upside was added today. The company now has substantially more financing visibility and a stated path toward Phase 3 and an NDA, but both the regulatory alignment and capital raise were already public. Against that standing expectation, the filing contributes a quarterly earnings miss and confirmation of increased spending, offset by a stronger balance-sheet position and no reported setback to EB613’s registrational plan.